Published in Medical Letter on the CDC and FDA, June 14th, 2006
The drug is approved for use as initial monotherapy in early PD and as adjunct therapy to levodopa in moderate-to-advanced disease. It is expected to become available later this year in two dosage strengths.
"Three placebo-controlled clinical trials demonstrated that rasagiline (Azilect) showed positive effects on motor impairments and activities of daily living in early PD and in moderate-to-advanced stage patients, and was well tolerated," said Ira Shoulson, MD, professor of neurology at the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.